generalised myasthenia gravis
Neurology · 2024–2026
7decisions
4medicines
5carried consumer input
101individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| efgartigimod alfa Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. | Mar 2026 | Recommended with restriction | no section in document |
| zilucoplan Treatment of generalised myasthenia gravis (gMG) in adult patients with anti-acetylcholine receptor (AChR) antibody positive status who are refractory to… | Mar 2025 | Recommended with restriction | input received Myasthenia Alliance Australia |
| rozanolixizumab Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. | Mar 2025 | Recommended with restriction | 17 individuals Myasthenia Alliance Australia |
| efgartigimod alfa Add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody… | Nov 2025 | Recommended with restriction | unclear |
| rozanolixizumab Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive, as an alternative bridging… | Nov 2025 | Recommended with restriction | 17 individuals Myasthenia Alliance Australia |
| ravulizumab Treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and remain symptomatic… | Jul 2024 | Not recommended | 36 individuals |
| zilucoplan Treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive, in combination with standard… | Jul 2024 | Not recommended | 31 individuals |
Who spoke
Myasthenia Alliance Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 7 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.